Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;12(2):337-342.
doi: 10.1007/s40120-023-00438-z. Epub 2023 Feb 4.

Unmet Needs in Preventive Treatment of Migraine

Enrico Bentivegna  1   2 , Dilara Onan  3   4 , Paolo Martelletti  3   5
Affiliations

Unmet Needs in Preventive Treatment of Migraine

Enrico Bentivegna et al. Neurol Ther. 2023 Apr.

Abstract

Migraine represents the most common cause of work disability in young women and the second one in the general population. Preventive treatment can reduce the frequency of attacks and their intensity, consequently improving the quality of life. Despite this, global health systems have shown important gaps in addressing optimal management of preventive therapy. Despite numerous adverse effects of traditional medications for migraine prevention being well known, these medications continue to be considered the standard of care for prophylaxis of this disease in many contexts. On the other hand, the widespread use of calcitonin gene-related peptide (CGRP) receptor antagonists, which have marked a breakthrough in prophylactic therapy of migraine, has been limited because of their high cost. We also highlight important shortcomings in migraine management by general practitioners (GPs) and poor patient education on the disease with a consequent delay in referring selected patients to dedicated headache centres. Over the next few years, we expect the headache medicine community to mobilize to address these gaps in preventive treatment of migraine.

Keywords: Antimigraine drugs; Calcitonin gene-related peptide (CGRP) receptor antagonists; Migraine education; Migraine prevention.

PubMed Disclaimer

References

    1. Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34. doi: 10.1186/s10194-022-01402-2. - DOI - PMC - PubMed
    1. Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi: 10.1186/s10194-020-01208-0. - DOI - PMC - PubMed
    1. Kang S, Eum S, Chang Y, et al. Burden of neurological diseases in Asia from 1990 to 2019: a systematic analysis using the Global Burden of Disease Study data. BMJ Open. 2022;12(9):e059548. doi: 10.1136/bmjopen-2021-059548. - DOI - PMC - PubMed
    1. Kim BK, Chu MK, Yu SJ, et al. Burden of migraine and unmet needs from the patients’ perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain. 2021;22(1):45. doi: 10.1186/s10194-021-01250-6. - DOI - PMC - PubMed
    1. Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20(1):111. doi: 10.1186/s10194-019-1062-4. - DOI - PMC - PubMed